# A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

> **NCT00113412** · PHASE2 · UNKNOWN · sponsor: **Samaritan Pharmaceuticals, Inc** · enrollment: 32 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** SP01A

## Key facts

- **NCT ID:** NCT00113412
- **Lead sponsor:** Samaritan Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 32 (—)
- **Last updated:** 2006-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113412, "A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00113412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*